Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 29

1.

The PI3K Pathway: Background and Treatment Approaches.

Lux MP, Fasching PA, Schrauder MG, Hein A, Jud SM, Rauh C, Beckmann MW.

Breast Care (Basel). 2016 Dec;11(6):398-404. doi: 10.1159/000453133. Epub 2016 Dec 8. Review.

PMID:
28228706
2.

Combined Inhibition of Both p110α and p110β Isoforms of Phosphatidylinositol 3-Kinase Is Required for Sustained Therapeutic Effect in PTEN-Deficient, ER+ Breast Cancer.

Hosford SR, Dillon LM, Bouley SJ, Rosati R, Yang W, Chen VS, Demidenko E, Morra RP Jr, Miller TW.

Clin Cancer Res. 2017 Jun 1;23(11):2795-2805. doi: 10.1158/1078-0432.CCR-15-2764. Epub 2016 Nov 30.

PMID:
27903677
3.

Establishment and antitumor effects of dasatinib and PKI-587 in BD-138T, a patient-derived muscle invasive bladder cancer preclinical platform with concomitant EGFR amplification and PTEN deletion.

Chang N, Lee HW, Lim JE, Jeong DE, Song HJ, Kim S, Nam DH, Sung HH, Jeong BC, Seo SI, Jeon SS, Lee HM, Choi HY, Jeon HG.

Oncotarget. 2016 Aug 9;7(32):51626-51639. doi: 10.18632/oncotarget.10539.

4.

Partial PTEN deletion is linked to poor prognosis in breast cancer.

Lebok P, Kopperschmidt V, Kluth M, Hube-Magg C, Özden C, B T, Hussein K, Mittenzwei A, Lebeau A, Witzel I, Wölber L, Mahner S, Jänicke F, Geist S, Paluchowski P, Wilke C, Heilenkötter U, Simon R, Sauter G, Terracciano L, Krech R, von d Assen A, Müller V, Burandt E.

BMC Cancer. 2015 Dec 16;15:963. doi: 10.1186/s12885-015-1770-3.

5.

Targeting PTEN-defined breast cancers with a one-two punch.

Maggi LB Jr, Weber JD.

Breast Cancer Res. 2015 Apr 8;17:51. doi: 10.1186/s13058-015-0566-3.

6.

Correlation between activation of PI3K/AKT/mTOR pathway and prognosis of breast cancer in Chinese women.

Deng L, Chen J, Zhong XR, Luo T, Wang YP, Huang HF, Yin LJ, Qiu Y, Bu H, Lv Q, Zheng H.

PLoS One. 2015 Mar 27;10(3):e0120511. doi: 10.1371/journal.pone.0120511. eCollection 2015.

7.

Overcoming endocrine resistance due to reduced PTEN levels in estrogen receptor-positive breast cancer by co-targeting mammalian target of rapamycin, protein kinase B, or mitogen-activated protein kinase kinase.

Fu X, Creighton CJ, Biswal NC, Kumar V, Shea M, Herrera S, Contreras A, Gutierrez C, Wang T, Nanda S, Giuliano M, Morrison G, Nardone A, Karlin KL, Westbrook TF, Heiser LM, Anur P, Spellman P, Guichard SM, Smith PD, Davies BR, Klinowska T, Lee AV, Mills GB, Rimawi MF, Hilsenbeck SG, Gray JW, Joshi A, Osborne CK, Schiff R.

Breast Cancer Res. 2014 Sep 11;16(5):430. doi: 10.1186/s13058-014-0430-x.

8.

Clinical potential of novel therapeutic targets in breast cancer: CDK4/6, Src, JAK/STAT, PARP, HDAC, and PI3K/AKT/mTOR pathways.

Hosford SR, Miller TW.

Pharmgenomics Pers Med. 2014 Aug 6;7:203-15. doi: 10.2147/PGPM.S52762. eCollection 2014. Review.

9.

Research on drug resistance mechanism of trastuzumab caused by activation of the PI3K/Akt signaling pathway.

Chen X, Wang H, Ou-Yang XN, Xie FW, Wu JJ.

Contemp Oncol (Pozn). 2013;17(4):363-9. doi: 10.5114/wo.2013.35292. Epub 2013 Oct 7.

10.

Endocrine resistance in breast cancer: focus on the phosphatidylinositol 3-kinase/akt/mammalian target of rapamycin signaling pathway.

Hasson SP, Rubinek T, Ryvo L, Wolf I.

Breast Care (Basel). 2013 Aug;8(4):248-55. doi: 10.1159/000354757. Review.

11.

Luminal breast cancer cell lines overexpressing ZNF703 are resistant to tamoxifen through activation of Akt/mTOR signaling.

Zhang X, Mu X, Huang O, Xie Z, Jiang M, Geng M, Shen K.

PLoS One. 2013 Aug 26;8(8):e72053. doi: 10.1371/journal.pone.0072053. eCollection 2013.

12.

PTEN mutation, methylation and expression in breast cancer patients.

Zhang HY, Liang F, Jia ZL, Song ST, Jiang ZF.

Oncol Lett. 2013 Jul;6(1):161-168. Epub 2013 May 8.

13.

Effects of indomethacin on expression of PTEN tumour suppressor in human cancers.

Abdulkareem IH, Blair M.

Niger Med J. 2013 Mar;54(2):100-6. doi: 10.4103/0300-1652.110041.

14.

mTOR signaling feedback modulates mammary epithelial differentiation and restrains invasion downstream of PTEN loss.

Ghosh S, Varela L, Sood A, Park BH, Lotan TL.

Cancer Res. 2013 Aug 15;73(16):5218-31. doi: 10.1158/0008-5472.CAN-13-0429. Epub 2013 Jun 17.

15.

New and emerging treatments for estrogen receptor-positive breast cancer: focus on everolimus.

Paplomata E, O'Regan R.

Ther Clin Risk Manag. 2013;9:27-36. doi: 10.2147/TCRM.S30349. Epub 2013 Jan 14.

16.

The impact of PTEN tumor suppressor gene on acquiring resistance to tamoxifen treatment in breast cancer patients.

Tanic N, Milovanovic Z, Tanic N, Dzodic R, Juranic Z, Susnjar S, Plesinac-Karapandzic V, Tatic S, Dramicanin T, Davidovic R, Dimitrijevic B.

Cancer Biol Ther. 2012 Oct;13(12):1165-74. doi: 10.4161/cbt.21346. Epub 2012 Aug 15.

17.
18.

Integrative Analysis of Response to Tamoxifen Treatment in ER-Positive Breast Cancer Using GWAS Information and Transcription Profiling.

Hicks C, Kumar R, Pannuti A, Miele L.

Breast Cancer (Auckl). 2012;6:47-66. doi: 10.4137/BCBCR.S8652. Epub 2012 Feb 20.

19.

Mutations in the phosphatidylinositol 3-kinase pathway: role in tumor progression and therapeutic implications in breast cancer.

Miller TW, Rexer BN, Garrett JT, Arteaga CL.

Breast Cancer Res. 2011;13(6):224. doi: 10.1186/bcr3039. Epub 2011 Nov 1. Review.

20.

Phosphatidylinositol 3-kinase and antiestrogen resistance in breast cancer.

Miller TW, Balko JM, Arteaga CL.

J Clin Oncol. 2011 Nov 20;29(33):4452-61. doi: 10.1200/JCO.2010.34.4879. Epub 2011 Oct 17. Review.

Supplemental Content

Support Center